Overview

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Leucovorin